Sunshine Guojian Pharmaceutical Co., Ltd. (SHA: 688336) released its third‑quarter 2026 report, recording total revenue of RMB 1.392 billion (up 24.77% year‑over‑year) and net profit attributable to shareholders of RMB 587 million (up 47.29% year‑over‑year) for the first three quarters of 2026, driven by steady operational growth, high‑efficiency pipeline execution, and the market approvals of two self‑developed Class 1 innovative biologics – anmuquitamab and anfrequitamab.
Financial Highlights – 9M 2026
| Metric | 9M 2026 Result | YoY Change |
|---|---|---|
| Total Revenue | RMB 1.392 billion | +24.77% |
| Net Profit Attributable to Shareholders | RMB 587 million | +47.29% |
| Operational Trend | Steady growth maintained | – |
| Pipeline Execution | High‑efficiency advancement across multiple programs | – |
| Q3 Standalone Detail | Not disclosed separately | – |
Net profit grew nearly twice as fast as revenue, indicating expanding operating leverage as newly approved products begin contributing to the commercial portfolio.
Product Approvals – Two Class 1 Innovative Biologics
- Anmuquitamab Injection: Approved for adult patients with moderate‑to‑severe plaque psoriasis who are candidates for systemic therapy or phototherapy – entering one of the largest and most competitive immunology markets.
- Anfrequitamab Injection: Approved for the treatment of acute gouty arthritis flare‑ups in adult patients who have contraindications to, intolerance of, or lack of efficacy with NSAIDs and/or colchicine, and for whom repeated courses of steroids are not appropriate – addressing a well‑defined, high‑unmet‑need population with limited therapeutic alternatives.
- Significance: Both products are self‑developed Class 1 innovative biologics, underscoring Sunshine Guojian’s transition from an established antibody manufacturer to a commercial‑stage innovator in autoimmune disease.
Pipeline Strategy & Modality Expansion
- Core Franchise: Deepening its presence in the autoimmune disease sector, guided by unmet clinical needs.
- Next‑Generation Modalities: Actively accelerating its strategic footprint in bispecific antibodies, T‑cell engagers (TCEs), and oral peptides to continuously enrich its autoimmune product pipeline.
- Target Expansion: Building a pipeline of next‑generation high‑value targets and innovative molecules, while accelerating development timelines across in‑flight projects.
- Platform Advantage: Leveraging long‑established antibody R&D and industrialization capabilities to advance translation of innovative achievements and steadily execute commercialization of new products.
- Pipeline Detail: Specific program names, phases and timelines for bispecific/TCE/oral peptide candidates were not disclosed.
Market Impact & Outlook
- Growth Quality: A 47.29% surge in attributable net profit against 24.77% revenue growth signals improving margins and disciplined cost structure as the innovation pipeline converts to commercial output.
- Commercial Ramp: With anmuquitamab and anfrequitamab now approved, the company enters a launch‑execution phase in psoriasis and acute gouty arthritis – both sizable Chinese markets with expanding biologic penetration.
- Strategic Positioning: Expansion into bispecific antibodies, TCEs and oral peptides aligns Sunshine Guojian with the industry’s shift toward multi‑specific and oral biologics formats, broadening long‑term optionality beyond monoclonal antibodies.
- Forward Plan: The company will remain guided by unmet clinical needs, expand its next‑generation pipeline, and accelerate the translation and commercialization of innovative achievements.
Forward‑Looking Statements
This brief contains forward‑looking statements regarding commercialization execution, pipeline development, and financial performance of Sunshine Guojian. Actual results may differ materially due to risks including product launch adoption, reimbursement and pricing dynamics, clinical and regulatory outcomes for pipeline candidates, and competitive pressure in the autoimmune market.-Fineline Info & Tech
